Like Omiq, Inc.

closed 1/19/2022 via BusinessWire

InsightfulScience, acquired Omiq, Inc.

See 37 Comparable Transactions
synopsis: Insightful Science acquired Omiq Inc, a company specialized in data science SaaS solutions for high dimensional flow cytometry and quantitative multi-omics data. OMIQ's flexible cloud platform enables researchers to identify drug or therapeutic interactions with a biological system through the tracking of biomarkers within lab samples.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: Omiq, Inc.
OMIQ is a modern cytometry analysis platform that bridges the world of machine learning and analytical pipelines with that of classical manual analysis. The company's flexible cloud platform allows researchers to complete their entire workflow using one software.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/11/2019 via PR Newswire

InVitae, will acquire Jungla Inc.

See 21 Comparable Transactions
synopsis: Invitae, a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare, will acquire Jungla, an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests.
buyer: InVitae (NVTA:$460.45)
Invitae is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare. They aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. "
 target: Jungla Inc.
Jungla Inc. is an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests. Jungla's technologies combine advances in functional genomics, computational biophysics, cellular engineering, and computer science.
price ($mm)
$50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/14/2019 via PR Newswire

GraphPad Software, Inc., acquired SnapGene

See 22 Comparable Transactions
synopsis: GraphPad Software, the leading provider of software developed exclusively for the scientific community, announced it has acquired SnapGene, a leading bioinformatics software solution that provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
buyer: GraphPad Software, Inc.
GraphPad is the leading provider of software developed exclusively for the scientific community. GraphPad Prism, their flagship product, is the preferred analysis and graphing solution for scientific research. Prism helps scientists discover and share the story in their data. "
 target: SnapGene
SnapGene was founded by scientists and software designers to meet the everyday needs of molecular biologists. Their software provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2011 via BusinessWire

PerkinElmer, Inc., acquired Geospiza

See 21 Comparable Transactions
synopsis: PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced that it has acquired Geospiza, Inc., a leading developer of software systems for the management of genetic analysis and laboratory workflows delivered through a Web-based secure cloud computing environment.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. It designs, manufactures and delivers advanced technology solutions that address the world's most critical health and safety concerns. "
 target: Geospiza
Designed by biologists for biologists, Geospiza is the developer of GeneSifter® software, providing integrated solutions for Next Generation Sequencing analysis and LIMS. Geospiza has set the industry standard for high value, low cost, “out of the box” solutions serving the life sciences market.
price ($mm)
$13
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/23/2021 via PR Newswire

InsightfulScience, will acquire Dotmatics

See 18 Comparable Transactions
synopsis: Insightful Science, a leading software provider, will acquire UK-based Dotmatics, an industry leading cloud-based scientific R&D data management platform. By integrating Insightful Science's software applications into Dotmatics cloud-first enterprise data management solution, the company will provide an end-to-end scientific research platform.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target parent: Scottish Equity Partners
target: Dotmatics
UK-based Dotmatics is a scientific informatics software and services company that is driving the automation of laboratory workflows for discovery and innovation research—accelerating the journey towards full digitalization and the Lab of the Future.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/5/2019 via PR Newswire

Beckman Coulter, Inc, acquired Cytobank

See 24 Comparable Transactions
synopsis: Beckman Coulter, a company that is advancing healthcare to enhance the diagnostic laboratory’s role in improving healthcare outcomes, announced its acquisition of Cytobank, a cloud-based analysis platform utilizing machine learning algorithms for collaborative biomedical research.
buyer parent: Danaher Corporation
buyer: Beckman Coulter, Inc (BEC:$3,260.60)
Beckman Coulter is committed to advancing healthcare by applying science, technology and the creativity of their teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Their diagnostic systems are used in complex biomedical testing and are found around the globe. "
 target: Cytobank
Cytobank Inc. is a cloud-based analysis platform utilizing machine learning algorithms for collaborative biomedical research. Pharmaceutical, biotechnology, and academic researchers around the world use their SaaS solution to develop deep understandings of complex biology at the single cell level.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/2/2015 via PR Newswire

Tute Genomics, acquired Knome, Inc.

See 17 Comparable Transactions
synopsis: Tute Genomics, the leader in clinical sequencing infomatics, announced its acquisition of key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commericial advancements in modern human genetics.
buyer: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights. "
 target: Knome, Inc.
Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/11/2021 via BusinessWire

Komodo Health Inc., acquired Mavens

See 17 Comparable Transactions
synopsis: Komodo Health has announced its acquisition of Mavens, the pioneer in building trusted software products and implementing cloud-based technology to help biotech, rare disease, and specialty pharma companies navigate the challenges of commercialization.
buyer: Komodo Health Inc.
At Komodo Health, they partner with their customers to improve patient care and reduce disease burden through data-driven insights. The Komodo Health Platform delivers patient-level insights by dynamically analyzing the broadest array of data across patients, practitioners, and health systems. "
 target: Mavens
Mavens is the pioneer in building trusted software products and implementing cloud-based technology to help biotech, rare disease, and specialty pharma companies navigate the challenges of commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/12/2018 via BusinessWire

Medidata Solutions Worldwide, will acquire SHYFT Analytics

See 17 Comparable Transactions
synopsis: Medidata announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics.
buyer: Medidata Solutions Worldwide (MDSO:$660.00)
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. "
 target: SHYFT Analytics
SHYFT Analytics is the leading cloud data analytics platform for life sciences with solutions designed exclusively for the pharmaceutical and biotech industry.
price ($mm)
$195
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2022 via Company Press Release

ImmunoPrecise, will acquire BioStrand BV

See 21 Comparable Transactions
synopsis: IPA (ImmunoPrecise Antibodies) will acquire BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”), a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology. BioStrand is a revolutionary cloud-based solution to perform genetics research faster and more accurately.
buyer: ImmunoPrecise (TSXV:IPA:$14.38)
ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™. "
 target: BioStrand BV
BioStrand is a revolutionary cloud-based solution to perform genetics research faster and more accurately. Make genomic analysis effective. BioStrand offers an AI-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns.
price ($mm)
$22
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2016 via BNC Analysis

bioMérieux S.A., acquired Applied Maths

See 22 Comparable Transactions
synopsis: bioMérieux, a world leader in the field of in vitro diagnostics, announced the acquisition of Applied Maths, a company that develops state-of-the-art software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data.
buyer: bioMérieux S.A. (:$1,996.55)
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. "
 target: Applied Maths
Applied Maths develops cutting-edge software for the biosciences. The company has gained worldwide recognition with its software GelCompar for the analysis of 1D gel patterns, and later even more with BioNumerics, a software suite for integrated databasing and analysis of biological data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/28/2013 via Company Press Release

Illumina, Inc., acquired NextBio, Inc.

See 14 Comparable Transactions
synopsis: Illumina, Inc. has acquired Santa Clara-based NextBio, a leader in clinical and genomic informatics. NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data.
buyer: Illumina, Inc. (ILMN:$3,556.00)
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. They provide innovative sequencing and array-based solutions. "
 target: NextBio, Inc.
NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/8/2021 via Company Press Release

Recuro Health, Inc., acquired MyLifeIQ

See 11 Comparable Transactions
synopsis: Recuro Health, an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, announced the acquisition of MyLifeIQ, an epigenetics platform that transitions healthcare to precision medicine.
buyer: Recuro Health, Inc.
Recuro Health delivers value throughout the healthcare ecosystem with digital solutions that respond to ongoing changes in the health care system. Recuro's holistic, integrated, and interoperable solutions create a personalized digital medical home that results in better outcomes and lower costs. "
 target: MyLifeIQ
MyLifeIQ is an epigenetics platform that transitions healthcare to precision medicine. By simplifying and customizing health information to unlock an individual’s full potential, the model builds an intuitive health intelligence platform that moves beyond the silos in healthcare.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/18/2019 via BNC Analysis

NVIDIA Corporation, acquired Parabricks

See 20 Comparable Transactions
synopsis: Computational technology company Nvidia has acquired sequencing analysis software developer Parabricks. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
buyer: NVIDIA Corporation (NVDA:$26,914.00)
NVIDIA Corporation is the worldwide leader in programmable graphics processor technologies. The Company creates innovative, industry-changing products for computing, consumer electronics, and mobile devices. "
 target: Parabricks
Parabricks is a sequencing analysis software developer. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/14/2018 via BusinessWire

Illumina, Inc., acquired Edico Genome Inc.

See 22 Comparable Transactions
synopsis: Illumina, Inc.  announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing. Edico Genome’s DRAGEN Bio-IT Platform uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
buyer: Illumina, Inc. (ILMN:$3,556.00)
Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. "
 target: Edico Genome Inc.
Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Their vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2016 via BusinessWire

PierianDx, acquired Tute Genomics

See 22 Comparable Transactions
synopsis: PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced the acquisition of Tute Genomics, a genomics software company based in Provo, UT. The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs.
buyer: PierianDx
Founded in 2011, PierianDx is the leading provider of genomic software. They enable health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. "
 target: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/26/2005 via PR Newswire

Entelos Inc., acquired Discovery Innovations, Inc.

See 811 Comparable Transactions
synopsis: Entelos, Inc., the leader in biosimulation technologies for pharmaceutical research and development, announced today the acquisition of Discovery Innovations, a specialized provider of data integration products and services to the life sciences.
buyer: Entelos Inc.
Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease and dramatically reduce the time and cost needed to develop them. Using our patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. "
 target: Discovery Innovations, Inc.
Discovery Innovations is a specialized provider of web-based products and information services to the life sciences. Recognizing the tidal wave of information being generated in the life sciences, Discovery Innovations has developed products and services that more efficiently access, deliver and sha
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/9/2022 via PR Newswire

Mentice AB, will acquire Ankyras

See 609 Comparable Transactions
synopsis: Mentice, a world leader in medical simulation solutions, will acquire Ankyras from Galgo Medical, a medical imaging software company in Spain. Ankyras is a Spanish software solution that reveals braided stent behavior. Ankyras enables users to create personalized predictive simulations of braided stents in the treatment of Intracranial aneurysms.
buyer: Mentice AB (OM:MNTC:$18.15)
Sweden-based Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. The company's solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. "
 target parent: Galgo Medical S.L.
target: Ankyras
Ankyras is a Spanish software solution that reveals braided stent behavior. Ankyras enables users to create personalized predictive simulations of braided stents in the treatment of Intracranial aneurysms for precise and safe implantation.
price ($mm)
$2.96
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/25/2020 via Company Press Release

Simcyp Limited, purchased Neurodegenerative Technology Assets from In Silico Biosciences, Inc.

See 46 Comparable Transactions
synopsis: Certara, the global model-informed drug development and decision support leader, has acquired a range of neurodegenerative diseases modeling and simulation technology assets from In Silico Biosciences, Inc., a company that offers computer simulation support in drug development.
buyer parent: Certara
buyer: Simcyp Limited
Certara’s Simcyp division is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. "
 seller: In Silico Biosciences, Inc.
The assets include a platform of multiple integrated quantitative systems pharmacology modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/6/2016 via PR Newswire

Twist Bioscience, acquired Genome Compiler Corporation

See 40 Comparable Transactions
synopsis: Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists.
buyer: Twist Bioscience
At Twist Bioscience, their expertise is accelerating science and innovation by leveraging the power of scale. They have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools. "
 target: Genome Compiler Corporation
Genome Compiler Corporation is an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists. Their aim is to build a best-in-class CAD system and a synthetic DNA marketplace for the new and growing community of biological designers around the world.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
Pages:  
closed 1/19/2022 via BusinessWire

InsightfulScience, acquired Omiq, Inc.

See 37 Comparable Transactions
synopsis: Insightful Science acquired Omiq Inc, a company specialized in data science SaaS solutions for high dimensional flow cytometry and quantitative multi-omics data. OMIQ's flexible cloud platform enables researchers to identify drug or therapeutic interactions with a biological system through the tracking of biomarkers within lab samples.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: Omiq, Inc.
OMIQ is a modern cytometry analysis platform that bridges the world of machine learning and analytical pipelines with that of classical manual analysis. The company's flexible cloud platform allows researchers to complete their entire workflow using one software.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2022 via BusinessWire

InsightfulScience, acquired Omiq, Inc.

See 37 Comparable Transactions
synopsis: Insightful Science acquired Omiq Inc, a company specialized in data science SaaS solutions for high dimensional flow cytometry and quantitative multi-omics data. OMIQ's flexible cloud platform enables researchers to identify drug or therapeutic interactions with a biological system through the tracking of biomarkers within lab samples.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: Omiq, Inc.
OMIQ is a modern cytometry analysis platform that bridges the world of machine learning and analytical pipelines with that of classical manual analysis. The company's flexible cloud platform allows researchers to complete their entire workflow using one software.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/22/2021 via BusinessWire

InsightfulScience, acquired Protein Metrics, Inc.

See 40 Comparable Transactions
synopsis: Insightful Science, the software company enabling the Cloud for scientific discovery, announced that it has completed the transaction to acquire Protein Metrics, Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: Protein Metrics, Inc.
Protein Metrics is a provider of biopharmaceutical and proteomics analysis software. The company's software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/10/2021 via BusinessWire

InsightfulScience, acquired LabArchives, LLC

See 150 Comparable Transactions
synopsis: Insightful Science, a life sciences software company, has acquired LabArchives, a widely used research data management application, serving 600,000 scientists in academic, non-profit and commercial organizations. The acquisition further solidifies Insightful Science’s leadership position in both corporate and academic markets.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: LabArchives, LLC
LabArchives is a suite of SaaS applications dedicated to better science used by more than 610,000 scientists to manage & protect research data, inventories & to manage resources. LabArchives products help scientists document their research data, prove and protect discovery, and collaborate securely.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2021 via BusinessWire

InsightfulScience, acquired De Novo Software, LLC

See 40 Comparable Transactions
synopsis: Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced that it has completed the transaction to acquire De Novo Software, the maker of FCS Express. FCS Express is the fastest-growing flow cytometry data analysis solution in the industry.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: De Novo Software, LLC
De Novo Software is a leading provider of flow and image cytometry data analysis. Its primary product, FCS Express, is used by over 3,000 laboratories worldwide for research purposes, and many clinical laboratories for high-throughput clinical analysis.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/23/2021 via PR Newswire

InsightfulScience, will acquire Dotmatics

See 18 Comparable Transactions
synopsis: Insightful Science, a leading software provider, will acquire UK-based Dotmatics, an industry leading cloud-based scientific R&D data management platform. By integrating Insightful Science's software applications into Dotmatics cloud-first enterprise data management solution, the company will provide an end-to-end scientific research platform.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target parent: Scottish Equity Partners
target: Dotmatics
UK-based Dotmatics is a scientific informatics software and services company that is driving the automation of laboratory workflows for discovery and innovation research—accelerating the journey towards full digitalization and the Lab of the Future.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/3/2020 via PR Newswire

InsightfulScience, acquired Statsols

See 256 Comparable Transactions
synopsis: Insightful Science has acquired Statsols, the developer of nQuery, the world's most trusted clinical trial design platform. nQuery is the software of choice for researchers who want to calculate sample size and power to optimize their clinical trial designs. It is proven to make clinical trials faster, less costly, and more successful.
buyer: InsightfulScience
Insightful Science is a technology company with category-leading software designed to empower scientists at every step of the research and development process. "
 target: Statsols
Statsols is the provider of nQuery, the complete trial design platform to make clinical trials faster, less costly, and more successful. nQuery is used to optimize clinical trial design in the largest biopharma companies, contract research organizations and research institutions worldwide.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2022 via BusinessWire

InsightfulScience, acquired Omiq, Inc.

See 37 Comparable Transactions
synopsis: Insightful Science acquired Omiq Inc, a company specialized in data science SaaS solutions for high dimensional flow cytometry and quantitative multi-omics data. OMIQ's flexible cloud platform enables researchers to identify drug or therapeutic interactions with a biological system through the tracking of biomarkers within lab samples.
buyer parent: Insight Venture Partners
buyer: InsightfulScience
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data. The company empowers life sciences researchers to plan effective experiments, connect with data, and extract insights so they can produce life-changing outcomes. "
 target: Omiq, Inc.
OMIQ is a modern cytometry analysis platform that bridges the world of machine learning and analytical pipelines with that of classical manual analysis. The company's flexible cloud platform allows researchers to complete their entire workflow using one software.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/14/2018 via BusinessWire

Illumina, Inc., acquired Edico Genome Inc.

See 22 Comparable Transactions
synopsis: Illumina, Inc.  announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing. Edico Genome’s DRAGEN Bio-IT Platform uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
buyer: Illumina, Inc. (ILMN:$3,556.00)
Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. "
 target: Edico Genome Inc.
Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Their vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/23/2017 via BusinessWire

Omicia, acquired Spiral Genetics

See 68 Comparable Transactions
synopsis: Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform.
buyer: Omicia
Clinicians and scientists utilize Omicia’s tools to quickly process and analyze genomic data and ultimately improve patient outcomes. Headquartered in Oakland, California, Omicia was founded by renowned scientists and industry veterans who are pioneers in bioinformatics, genomics and diagnostics. "
 target: Spiral Genetics
Headquartered in Seattle, WA, Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. They specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2016 via BusinessWire

PierianDx, acquired Tute Genomics

See 22 Comparable Transactions
synopsis: PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced the acquisition of Tute Genomics, a genomics software company based in Provo, UT. The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs.
buyer: PierianDx
Founded in 2011, PierianDx is the leading provider of genomic software. They enable health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. "
 target: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/25/2016 via Company Press Release

Vela Diagnostics Pte. Ltd., purchased Data Interpretation Division from Lifecode, Inc.

See 1096 Comparable Transactions
synopsis: Vela Diagnostics announced that it has acquired the data interpretation division of Lifecode Inc., a Foster City, California-based cancer molecular company. The data interpretation products and services from Lifecode will be connected to Vela Diagnostics’ Next-Generation Sequencing Sentosa® SQ Reporter Software.
buyer: Vela Diagnostics Pte. Ltd.
Vela Diagnostics is a worldwide supplier of integrated life sciences and diagnostic solutions that help provide customers with valuable molecular information. It delivers innovative technology and products* that address many of the clinical, technical and economic issues facing laboratories. "
 seller: Lifecode, Inc.
Lifecode Inc’s data interpretation service provides access to Lifecode’s data integration framework, interpretation and report generation pipelines. Lifecode is a specialized CLIA certified clinical laboratory focused on the genetic basis of human disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/4/2015 via BusinessWire

Agilent Technologies Inc., will acquire Cartagenia

See 41 Comparable Transactions
synopsis: Agilent Technologies Inc. will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs. Cartagenia provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays.
buyer: Agilent Technologies Inc. (A:$4,720.00)
Agilent Technologies Inc. is a global leader in life sciences, diagnostics and applied chemical markets. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. "
 target: Cartagenia
Cartagenia helps labs to confidently interpret, report and share genomic variants. Reduce turnaround time, build informed variant assessment pipelines, generate clinical grade lab reports, and manage increasing volumes of data. Bring together CNVs and molecular variation. Use clinical phenotypes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/11/2019 via PR Newswire

InVitae, will acquire Jungla Inc.

See 21 Comparable Transactions
synopsis: Invitae, a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare, will acquire Jungla, an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests.
buyer: InVitae (NVTA:$460.45)
Invitae is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare. They aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. "
 target: Jungla Inc.
Jungla Inc. is an artificial intelligence driven biotechnology company utilizing computational and cellular modeling to improve clinical genetic tests. Jungla's technologies combine advances in functional genomics, computational biophysics, cellular engineering, and computer science.
price ($mm)
$50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/18/2019 via BNC Analysis

NVIDIA Corporation, acquired Parabricks

See 20 Comparable Transactions
synopsis: Computational technology company Nvidia has acquired sequencing analysis software developer Parabricks. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
buyer: NVIDIA Corporation (NVDA:$26,914.00)
NVIDIA Corporation is the worldwide leader in programmable graphics processor technologies. The Company creates innovative, industry-changing products for computing, consumer electronics, and mobile devices. "
 target: Parabricks
Parabricks is a sequencing analysis software developer. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/27/2016 via BNC Analysis

Venaxis, Inc., will acquire Strand Life Sciences

See 1159 Comparable Transactions
synopsis: Venaxis, a developer of an in vitro diagnostic test for acute appendicitis, is to acquire Strand Life Sciences, a cancer genomics firm. Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
buyer: Venaxis, Inc. (BIOP:$0.01)
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1™ Test, which is designed to aid in the identification of patients at low risk for acute appendicitis. "
 target: Strand Life Sciences
Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/6/2016 via PR Newswire

Twist Bioscience, acquired Genome Compiler Corporation

See 40 Comparable Transactions
synopsis: Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists.
buyer: Twist Bioscience
At Twist Bioscience, their expertise is accelerating science and innovation by leveraging the power of scale. They have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools. "
 target: Genome Compiler Corporation
Genome Compiler Corporation is an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists. Their aim is to build a best-in-class CAD system and a synthetic DNA marketplace for the new and growing community of biological designers around the world.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/10/2018 via BusinessWire

Zymergen, acquired Radiant Genomics

See 24 Comparable Transactions
synopsis: Zymergen, a molecular technology company, announced the acquisition of Radiant Genomics, a leader in functional metagenomics research. Radiant Genomics has developed a robust industrial platform for natural product and gene discovery that allows scientists to rapidly identify, produce, and test products encoded in the genomes of organisms.
buyer: Zymergen
Zymergen is a molecular technology company ushering in a new age of manufacturing and industrial innovation. Leveraging the power of machine learning, automation, and bioengineering, they discover new molecular products that touch every industry. "
 target: Radiant Genomics
Radiant Genomics is a leader in functional metagenomics research. Radiant Genomics has developed a robust industrial platform for natural product and gene discovery that allows scientists to rapidly identify, produce, and test products encoded in the genomes of millions of organisms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/25/2020 via Company Press Release

N. Harris Computer Corporation, acquired Genial Genetic Solutions, Ltd.

See 47 Comparable Transactions
synopsis: Harris, a global vertical market software provider and acquirer, grows its UK presence with the acquisition of Genial. The Genial group is a highly regarded genetic laboratory information management software provider, specializing in the authoring, deployment, and support of the Shire and iGene Laboratory and Clinical Genetics Information Systems.
buyer parent: Constellation Software, Inc.
buyer: N. Harris Computer Corporation
Headquartered in Canada, Harris provides feature-rich and robust turnkey solutions to Public Sector, Schools, Utility, and Health Care agencies. Harris' focus is on creating long-term relationships with its customers and ensuring that it meets the changing needs of its customers over time. "
 target: Genial Genetic Solutions, Ltd.
The Genial group is a highly regarded genetic laboratory information management software provider, specializing in the authoring, deployment, and support of the Shire and iGene Laboratory and Clinical Genetics Information Systems.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/14/2019 via PR Newswire

GraphPad Software, Inc., acquired SnapGene

See 22 Comparable Transactions
synopsis: GraphPad Software, the leading provider of software developed exclusively for the scientific community, announced it has acquired SnapGene, a leading bioinformatics software solution that provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
buyer: GraphPad Software, Inc.
GraphPad is the leading provider of software developed exclusively for the scientific community. GraphPad Prism, their flagship product, is the preferred analysis and graphing solution for scientific research. Prism helps scientists discover and share the story in their data. "
 target: SnapGene
SnapGene was founded by scientists and software designers to meet the everyday needs of molecular biologists. Their software provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/16/2018 via PR Newswire

Sophia Genetics, acquired Interactive Biosoftware

See 41 Comparable Transactions
synopsis: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced that it has completed the acquisition of French-based tech company Interactive Biosoftware (IBS), the creators of Alamut®, the most used decision support software for clinical genomic data interpretation. Alamut® is currently deployed in over 450 hospitals.
buyer: Sophia Genetics
Based in Switzerland, SOPHiA GENETICS is a health tech company which has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients. "
 target: Interactive Biosoftware
Interactive Biosoftware was founded in Rouen, France, by a group of medical and computer scientists focusing on practical software applications for health care and life sciences, particularly in the field of genomics.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Wiley, purchased Informatics products from Bio-Rad Laboratories

See 53 Comparable Transactions
synopsis: John Wiley and Sons Inc., a global leader in research and education, announced the acquisition of Bio-Rad Laboratories, Inc.’s Informatics products including the company’s spectroscopy software and spectral databases.
buyer: Wiley (NYSE:JW.A:$1,864.09)
Wiley drives the world forward with research and education. Through publishing, platforms and services, they help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. "
 seller: Bio-Rad Laboratories (BIO:$2,311.66)
The acquisition includes the Informatics Spectroscopy Software and Spectral Databases from Bio-Rad Laboratories, a manufacturer of products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/10/2016 via PR Newswire

Sunquest Information Systems, acquired UNIConnect LC

See 25 Comparable Transactions
synopsis: Provider of diagnostics informatics solutions to more than 1,700 laboratories, Sunquest Information Systems, Inc. announced the acquisition of the Salt Lake City-based software firm UNIConnect® L.C. UNIConnect specializes in software for molecular laboratories and augments Sunquest's molecular diagnostics solution.
buyer parent: Roper Technologies, Inc.
buyer: Sunquest Information Systems
Sunquest Information Systems Inc. provides diagnostics informatics solutions to more than 1,700 laboratories. Since 1979, Sunquest has helped laboratories and healthcare organizations across the world optimize financial results, enhance efficiency and improve the quality of patient care. "
 target: UNIConnect LC
Based in Salt Lake City, UT, UNIConnect® L.C. has created a Laboratory Information Management System (LIMS) platform that marries breakthrough software technology with unparalleled customization and configuration control to advance the "omic" sciences and precision medicine.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/2/2015 via PR Newswire

Tute Genomics, acquired Knome, Inc.

See 17 Comparable Transactions
synopsis: Tute Genomics, the leader in clinical sequencing infomatics, announced its acquisition of key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commericial advancements in modern human genetics.
buyer: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights. "
 target: Knome, Inc.
Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2011 via BusinessWire

PerkinElmer, Inc., acquired Geospiza

See 21 Comparable Transactions
synopsis: PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced that it has acquired Geospiza, Inc., a leading developer of software systems for the management of genetic analysis and laboratory workflows delivered through a Web-based secure cloud computing environment.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. It designs, manufactures and delivers advanced technology solutions that address the world's most critical health and safety concerns. "
 target: Geospiza
Designed by biologists for biologists, Geospiza is the developer of GeneSifter® software, providing integrated solutions for Next Generation Sequencing analysis and LIMS. Geospiza has set the industry standard for high value, low cost, “out of the box” solutions serving the life sciences market.
price ($mm)
$13
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/5/2021 via Company Press Release

InVitae, acquired Genosity

See 775 Comparable Transactions
synopsis: Invitae, a leading medical genetics company, announced it has acquired Genosity Inc., a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests.
buyer: InVitae (NVTA:$460.45)
Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service. "
 target: Genosity
Genosity is a life science biotechnology company that employs its expertise, novel software solutions and laboratory services for both somatic and germline applications to enable its strategic partners to fully realize the value of precision medicine for both the research and clinical markets.
price ($mm)[EV]
$196 [$195]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/25/2020 via Company Press Release

Simcyp Limited, purchased Neurodegenerative Technology Assets from In Silico Biosciences, Inc.

See 46 Comparable Transactions
synopsis: Certara, the global model-informed drug development and decision support leader, has acquired a range of neurodegenerative diseases modeling and simulation technology assets from In Silico Biosciences, Inc., a company that offers computer simulation support in drug development.
buyer parent: Certara
buyer: Simcyp Limited
Certara’s Simcyp division is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. "
 seller: In Silico Biosciences, Inc.
The assets include a platform of multiple integrated quantitative systems pharmacology modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
Pages:  

Like Omiq, Inc.


read more

Omiq, Inc.

Jungla Inc.

SnapGene

Geospiza

Dotmatics

Cytobank

Knome, Inc.

Mavens

SHYFT Analytics

BioStrand BV

Applied Maths

NextBio, Inc.

MyLifeIQ

Parabricks

Edico Genome Inc.

Tute Genomics

Discovery Innovations, Inc.

Ankyras

In Silico Biosciences, Inc.

Genome Compiler Corporation

Pages:  
read more

Omiq, Inc.

read more

Omiq, Inc.

Protein Metrics, Inc.

LabArchives, LLC

De Novo Software, LLC

Dotmatics

Statsols

read more

Omiq, Inc.

Edico Genome Inc.

Spiral Genetics

Tute Genomics

Lifecode, Inc.

Cartagenia

Jungla Inc.

Parabricks

Strand Life Sciences

Genome Compiler Corporation

Radiant Genomics

Genial Genetic Solutions, Ltd.

SnapGene

Interactive Biosoftware

Bio-Rad Laboratories

UNIConnect LC

Knome, Inc.

Geospiza

Genosity

In Silico Biosciences, Inc.

Pages:  
Geography
Matching Companies
Ticker: CM:CLRX
 
 
 
 
 
 
 
 
CollabRX, Inc
CollabRX, Inc
CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts.
year
2014
rev ($mm)
$0.38
EBITDA ($mm)
($4.07)
EBIT ($mm)
($4.32)
Net Income ($mm)
Employees
1
  • drill down
  • watch
Ticker: CM:CLRX
 
 
 
 
 
 
 
 
CollabRX, Inc
CollabRX, Inc
CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts.
year
2014
rev ($mm)
$0.38
EBITDA ($mm)
($4.07)
EBIT ($mm)
($4.32)
Net Income ($mm)
Employees
1
  • drill down
  • watch
Ticker: TMO
 
 
 
 
 
 
 
 
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science, helping their customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.
year
2019
rev ($mm)
$24,630.00
EBITDA ($mm)
$6,242.00
EBIT ($mm)
$3,995.00
Net Income ($mm)
$3,174.00
Employees
70000
  • drill down
  • watch